<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Urologiia</journal-id><journal-title-group><journal-title xml:lang="en">Urologiia</journal-title><trans-title-group xml:lang="ru"><trans-title>Урология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1728-2985</issn><issn publication-format="electronic">2414-9020</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">322127</article-id><article-id pub-id-type="doi">10.18565/urology.2018.1.106-111</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">AFALAZA IN THE MANAGEMENT OF PATIENTS WITH CHRONIC PELVIC PAIN SYNDROME</article-title><trans-title-group xml:lang="ru"><trans-title>ПРИМЕНЕНИЕ ПРЕПАРАТА АФАЛАЗА В ЛЕЧЕНИИ БОЛЬНЫХ С СИНДРОМОМ ХРОНИЧЕСКОЙ ТАЗОВОЙ БОЛИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Neimark</surname><given-names>A. I</given-names></name><name xml:lang="ru"><surname>Неймарк</surname><given-names>А. И.</given-names></name></name-alternatives><bio xml:lang="en"><p>Dr.Med.Sci., Prof., Head of the Department of Specialized Surgery in Urology, Traumatology and Ophthalmology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зав. кафедрой специализированной хирургии по урологии, травматологии и офтальмологии</p></bio><email>urologagmu@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Neimark</surname><given-names>B. A</given-names></name><name xml:lang="ru"><surname>Неймарк</surname><given-names>Б. А.</given-names></name></name-alternatives><bio xml:lang="en"><p>Dr.Med.Sci., Prof. at the Department of Specialized Surgery in Urology, Traumatology and Ophthalmology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор кафедры специализированной хирургии по урологии, травматологии и офтальмологии</p></bio><email>urologagmu@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nozdrachev</surname><given-names>N. A</given-names></name><name xml:lang="ru"><surname>Ноздрачев</surname><given-names>Н. А.</given-names></name></name-alternatives><bio xml:lang="en"><p>Ph.D., Associate Professor at the Department of Specialized Surgery in Urology, Traumatology and Ophthalmology</p></bio><bio xml:lang="ru"><p>к.м.н. доцент кафедры специализированной хирургии по урологии, травматологии и офтальмологии</p></bio><email>nozdrachevuro@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kondrat’eva</surname><given-names>Yu. S</given-names></name><name xml:lang="ru"><surname>Кондратьева</surname><given-names>Ю. С.</given-names></name></name-alternatives><bio xml:lang="en"><p>Dr.Med.Sci., Prof., Head of the Department of Dermatovenereology, Cosmetology and Immunology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зав. кафедрой дерматовенерологиии, косметологии и иммунологии</p></bio><email>Juliajsk@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Borisenko</surname><given-names>D. V</given-names></name><name xml:lang="ru"><surname>Борисенко</surname><given-names>Д. В.</given-names></name></name-alternatives><bio xml:lang="en"><p>Clinical resident at the Department of Specialized Surgery in Urology, Traumatology and Ophthalmology</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры специализированной хирургии по урологии, травматологии и офтальмологии</p></bio><email>urologagmu@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Arkhipov</surname><given-names>D. O</given-names></name><name xml:lang="ru"><surname>Архипов</surname><given-names>Д. О.</given-names></name></name-alternatives><bio xml:lang="en"><p>6th year student, Head of SSS in Urology</p></bio><bio xml:lang="ru"><p>студент 6-го курса, староста СНО по урологии</p></bio><email>urologagmu@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Makarova</surname><given-names>A. A</given-names></name><name xml:lang="ru"><surname>Макарова</surname><given-names>А. А.</given-names></name></name-alternatives><bio xml:lang="en"><p>6th year student, Head of SSS in Urology</p></bio><bio xml:lang="ru"><p>студент 6-го курса, член СНО по урологии</p></bio><email>urologagmu@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Oberemok</surname><given-names>P. A</given-names></name><name xml:lang="ru"><surname>Оберемок</surname><given-names>П. А.</given-names></name></name-alternatives><bio xml:lang="en"><p>6th year student, Head of SSS in Urology</p></bio><bio xml:lang="ru"><p>студент 6-го курса, член СНО по урологии</p></bio><email>urologagmu@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Altai State Medical University of Minzdrav of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Алтайский государственный медицинский университет»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2018</year></pub-date><issue>1</issue><issue-title xml:lang="en">NO1 (2018)</issue-title><issue-title xml:lang="ru">№1 (2018)</issue-title><fpage>106</fpage><lpage>111</lpage><history><date date-type="received" iso-8601-date="2023-04-07"><day>07</day><month>04</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО «Бионика Медиа»</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/1728-2985/article/view/322127">https://journals.eco-vector.com/1728-2985/article/view/322127</self-uri><abstract xml:lang="en"><p>Introduction. Currently, chronic pelvic pain syndrome (CPPS) is one of the most prevalent urological diseases, but due to the multifactorial nature of the disease and the lack of consensus on its pathogenesis, the issue of adequate therapy remains open. Since the vascular factor plays the major role in the pathogenesis of CPPS, we hypothesized that this category of patients has microcirculatory disturbances of the prostate. Aim. Detection of microcirculatory disturbances of the prostate, their correction, and evaluation of the effect on the course of CPPS. Materials and methods. The study comprised 60 healthy, sexually active men with clinical manifestations of CPPS lasting from 6 months to 5 years. After a comprehensive examination, all patients received Afalaza 2 tablets twice daily for 16 weeks. At the end of week 16, patients were re-examined. Results. In patients with CPPS, therapy with Afalaza resulted in a significant improvement in microcirculation in the prostate thus leading to the reduction of the severity of disease manifestations.</p></abstract><trans-abstract xml:lang="ru"><p>Введение. В настоящее время синдром хронической тазовой боли (СХТБ) занимает одну из лидирующих позиций по распространенности среди урологических заболеваний, однако ввиду мультифакторности заболевания и отсутствия единого мнения о патогенезе СХТБ вопрос адекватной терапии остается открытым. Поскольку доказан факт вовлечения в патогенез СХТБ сосудистого компонента, нами была выдвинута теория, согласно которой у данной категории больных страдает в том числе микроциркуляторное звено кровоснабжения предстательной железы. Цель исследования: выявление изменений микроциркуляторного русла предстательной железы, их коррекция и оценка влияния на течение СХТБ. Материалы и методы. В исследование были включены 60соматически здоровых, сексуально активных мужчин, имевших клинические проявления СХТБ с продолжительностью заболевания от 6 мес. до 5 лет. После проведения комплексного обследования все включенные в исследование пациенты принимали препарат Афалаза по 2 таблетки 2 раза в сутки в течение 16 нед. По истечении 16 нед. проведены повторное обследование, оценка и сравнение полученных данных. Результаты. Применение препарата Афалаза больными синдромом хронической тазовой боли сопровождалось значительным улучшением микроциркуляции в предстательной железе, что позволило добиться уменьшения выраженности клинических проявлений заболевания.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic prostatitis</kwd><kwd>chronic pelvic pain syndrome</kwd><kwd>Afalaza</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хронический простатит</kwd><kwd>синдром хронической тазовой боли</kwd><kwd>Афалаза</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Davidov M.I. Etiology of chronic prostatitis. Plenum PravIeniya ROU: materialy. Saratov. 2004;333-334 p.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Loran O.B., Pushkar’ D.Yu., Segal A.S., Yudovskii S.O. Our understanding of the problem of chronic prostatitis. Farmateka. 2002;10:69-75.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Sivkov A.V., Romikh V.V., Zakharchenko A.V. IIIB Chronic prostatitis/chronic pelvic pain syndrome and sexual dysfunction. Andrologiya i genital’naya khirurgiya. 2015;4:18-26.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Keltikangas-Järvinen L. Role of psychological factors in somatic diseases: a challenge for current behavioral medicine. Ann Med. 1989;21(4):255-256.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>de la Rosette J.J., Ruijgrok M.C., Jeuken J.M., Karthaus H.F., Debruyne F.M. Personality variables involved in chronic prostatitis. UroIogy. 1993;42(6):654-662.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Mehik A., Hellström P., Sarpola A., Lukkarinen O., Järvelin M.R. Fears, sexual disturbances and personality features in men with prostatitis: a population-based cross-sectional study in Finland. BJU Int. 2001;88(1):35-38.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Berghuis J.P., Heiman J.R., Rothman I., Berger R.E. Psychological and physical factors involved in chronic idiopathic prostatitis. J Psychosom Res. 1996;41(4):313-325.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Krieger J.N., Nyherg L. Jr., Nickel J.S. NIH consensus definition and classification of prostatitis. JAMA 1999;282(3):236-237.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Loran O.B., Segal A.S. Chronic prostatitis. Materials X Russian Congress of urology. M., 2002. Р. 209-222.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>McNaughton Collins M., MacDonald R., Wilt T.J. Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Ann Intern Med. 2000;133(5):367-381.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mazo E.B., Koryakin M.B., Akopyan A.S. Hemodynamic prerequisites for the development of prostatitis in left-sided varicocele. Urologiya i nefrologiya. 1993;4:5-8.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Neimark A.I., Lomshakov A.A. Dopplerography in the diagnosis of chronicprostatitis.UroIogiia.2000;6:21-23</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Borovskaya T.G., Fomina T.I., Loskutova O.P., Baranova O.V., Sergeeva S.A., Martyushev A.V., Epshtein O.I. Antibodies to prostate-specific antigen in uItra-Iow doses: the effect on the morphological and functional state of the prostate of rats. ByulIeten’ eksperimental’noi i biologicheskoi meditsiny. 2002</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Dorofeev S.D., Kudryavtsev Yu.V., Kudryavtseva L.V. ImmunohistochemicaI aspects of chronic prostatitis. Effektivnaya farmakoterapiya. 2014;2:26-38.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Neimark A.I., Isaenko V.I., Yakovets Ya.V., Simashkevich A.V., Aliev R.T. Use of Afala in urology practice. Urologiia. 2009;3:67-70.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Neimark A.I., Aliev R.T., Muzalevskaya N.I., Krainichenko S.V., Vorob’eva E.N., Tarasova T.S. Use of Impaza in the management of erectiIe dysfunction in patients with essentiaI hypertension and ischemic heart disease. ByulIeten’ eksperimental’noi biologii i meditsiny. 2009;8:76-79.</mixed-citation></ref></ref-list></back></article>
